Insights+: EMA Marketing Authorization of New Drugs in August 2023

Shots:The EMA approved 5 New Chemical Entity (NCE) and 6 Biologic Drugs in August 2023, leading to treatments for patients and advances in the healthcare industryIn August 2023, the major highlight drugs were Aquipta (atogepant) approved for the preventive treatment of migraine in adults & Opdivo (nivolumab) as an adjuvant treatment for completely…

BySenior EditorSeptember 28, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2023

Shots:The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…

BySenior EditorSeptember 20, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2023

Shots:The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9BThe second quarter of the year also showcases multiple approvals of the therapies…

BySenior EditorJuly 3, 2023

Insights+: EMA Marketing Authorization of New Drugs in August 2023

PharmaShots’ Key Highlights of Second Quarter 2023

Contact US

OUR INFORMATION

FOLLOW US